Earlier is not automatically better.

@AtishChoudhury MD, PhD, considers the right timing for radiopharmaceuticals in metastatic prostate cancer.

Explore the debates at hubs.ly/Q04xcr8v0

#OLNGreatDebates

🚨 ARTO long-term update in oligometastatic mCRPC:

SBRT to all mets + abi/ADT vs abi/ADT alone.

@TheLancetOncol

👥 157 pts
🎯 ≤3 bone/nodal mets
💊 Abiraterone + ADT ± MDT/SBRT
⏱️ Median follow-up: 53 mo

Results:
✅ OS: NR vs 50 mo
✅ HR 0.55, p=0.021
✅ bPFS: 44 vs 18 mo
C-specific survival improved
✅ No major toxicity signal from adding SBRT

Big signal: MDT may be more than “delay next therapy” in oligometastatic CRPC.

Caveat: phase 2, unplanned OS analysis, not originally powered for OS.

Still: hard to ignore. 🔥

🔗shorturl.at/rEx5L

@PCFnews @PCF_Science @urotoday @renalandurology @UrologyTimes #prostatecancer

Interesting study demonstrating equivalent long-term outcomes with treatment continuation vs interruption in exceptional responders to PARPi in PS-ROC. May support strategy of PARPi interruption in exceptional responders in met PrCa as well.
jamanetwork.com/journals/jamao…

📈 In this interview, @AtishChoudhury, of @DanaFarber, discusses the key findings from the A-DREAM trial thatevaluated ADT interruption in patients with metastatic hormone-sensitive #prostatecancer who responded well to an androgen receptor pathway inhibitor: buff.ly/X39QmSz

DE-ESCALATE (@EORTC): A pragmatic trial to revisit intermittent ADT in mHSPC in the era of new ARPIs @urotoday #ASCO26

🌟n=1,600
🌟Key elig criteria: mHSPC pts, PSA ≤ 0.2 at 6-12 mos after Rx start
🌟2:1 randomization to cMAB vs iMAB
🌟Co-primary EPs: (i) feasibility (ii) s: May 1, 2026: 211 pts enrolled

DREAM/Alliance A032101 presented by @DanaFarber's Dr. Atish Choudhury (@AtishChoudhury) at #ASCO26 shows 41% of favorable responders to testosterone suppression + ARPI remaining treatment-free w/testosterone recovery at 18 months after treatment interruption.

CC: @DanaFarber_GU

CLEARED: Comeback from long course ADT with relugolix and daro in hormone-sensitive PCa @AtishChoudhury @urotoday #ASCO26

🌟Rel + Daro: safe, well-tolerated during first 6 cycles -- PK parameters similar to historical mono Rel
🌟Pts will be followed after end of Rx for 1 EP of T recovery

Two Alliance oral abstract presentations today at #ASCO26 spotlight efforts to optimize treatment for men with advanced #prostatecancer. @AtishChoudhury presents A-DREAM (A032101) and @CAPsurvivorship presents ARACOG (AFT-47) #NCI #NCTN #GUOnc #CancerResearch @DanaFarber

So proud of our Gelb Center for Translational Research manager Jasmine Lee for her poster summarizing our experience with on-treatment PSMA PET/CT in patients receiving ADT+ARPI for mHSPC, with a majority eventually being able to take a treatment break. @DanaFarber_GU

Of the 19 patients with negative PET, 16 interrupted treatment, of whom only 3 resumed to date. Of the 36 patients with previously untreated PSMA avid disease, 11 received RT to residual disease, and 18 interrupted treatment of whom only 6 resumed to date.

At #ASCOGU26: @AtishChoudhury details research that addresses what happens with PSMA PET/CT imaging for patients who present with metastatic prostate cancer and start hormone treatments. @DanaFarber_GU @DanaFarber

How early is too early for lutetium PSMA in metastatic prostate cancer?

The data is evolving and comfort with the therapy is growing, but sequencing remains unsettled.

Should lutetium PSMA move forward in mCRPC while patients are fitter and disease burden may be lower? Or is en reserved for later lines, after AR targeted therapy and chemotherapy?

At #OLNGreatDebates, @kai_tsao, MD, MS, and @AtishChoudhury MD, PhD take opposing positions on when this therapy truly delivers the most value.

Hear both sides. Then decide where you stand.

Join us: hubs.ly/Q044VHJH0

#ProstateCancer #GUOncology #mCRPC

Thank you for the kind invitation to give this talk to such an esteemed group! I appreciate the warm reception from @DoctorSotelo, Leo Doumanian, Inderbill Gill and the rest of the team, and I found the sessions to be very enlightening.

Dr. @AtishChoudhury reviews oral relugolix vs injectable leuprolide for androgen deprivation therapy in #ProstateCancer, including HERO trial outcomes and new insights on cardiovascular risk with oral therapy.

🎦Watch the video: ascopost.com/videos/themati…

Don't know how Sipuleucel-T (Provenge) works - or how we can make it better? 🤔 Check out our hot-off-the-press review in @jitcancer 🔥 Sip-T was the FIRST approved cellular vaccine therapy for ANY cancer (2010)!
jitc.bmj.com/content/13/12/…

Congratulations to @autumngagnonn on her publication demonstrating in pts treated with defined course ADT+abi that early d/c of LHRH-A allowed ongoing castrate T with abi mono but earlier and more reliable T recovery after stopping. @DanaFarber_GU secure-web.cisco.com/1Hbfbiu2acxvln…

It's that time of year again! Please consider joining BellissiMo at movember.com/t/bellissimo?m… to support Movember's efforts towards prostate cancer, testicular cancer and mental health research and resources. Thank you @Movember for highlighting my journey. us.movember.com/story/from-res…

Just in @TheLancetOncol 👉Ph3 CYCLONE 2: Abemaciclib + abiraterone vs. abi did not improve rPFS (primary endpoint) in mCRPC #ProstateCancer. Higher-risk pts (M1 at dx, Gleason ≥8, ⬆️PSA) seem to benefit more @OncoAlert @urotoday @PCF_Science Link👉 bit.ly/43HvEZJ

Tazemetostat + talazoparib for metastatic castration-resistant #ProstateCancer. @AtishChoudhury @DanaFarber joins Evan Yu, MD @fredhutch to discuss a first-in-human trial combining EZH2 and PARP inhibition in #mCRPC. #WatchNow on UroToday > bit.ly/4oVI9tJ

Truly a joy to participate in @TheJimmyFund Radio-Telethon with Kevin! audacy.com/podcast/weei-a…